Abionic launched its first allergy test

Please login or
register
22.05.2015

Good news from Abionic: The start-up from Lausanne has launched its allergy test successfully and announced the incorporation of its US subsidiary in Boston.

Abionic announced that it has launched its first allergy test on the market, allowing quantification of allergy level in only 5 minutes. Abionic CEO Nicolas Durand comments: “Starting commercialization is one of the most important step for a start-up company: it means that we succeeded in bringing a new technology to a real certified product on the market. We are definitively entering an exciting phase!” The first sales have been realized in Switzerland. Abionic plans to start European sales at the next EAACI Congress (European Academy of Allergy and Clinical Immunology) which will take place in June. In addition to the launch the company announced the incorporation of its US subsidiary in Boston, MA, that will support its internationalization strategy.

Abionic uses highly advanced technologies to provide the medical profession with a novel diagnostic tool designed to give patients personal allergy profiles. Abionic technology is intuitive (users do not need special training), the test is painless for the patient and the device provides a clear, concise result for up to 10 different allergens within 20 minutes.

A video can be found in our video section.

Operating the abioSCOPE (reader) is straightforward. The patient’s blood sample is mixed with a proprietary reagent and placed into a special test capsule that contains multiple biosensors capable of detecting a specific range of allergies. The capsule is placed into a disc mounting plate that is then inserted into the abioSCOPE, in the same way that a DVD is inserted into a player. The results are then presented on a touch screen and saved onto a standard SD card.

The free abioGUIDE mobile application allows the user to immediately see the results from the abioSCOPE directly on his own mobile platform. The user can easily send the full reports to his computer, to the patient by email (PDF generated reports) or print them. He can also access a full allergens database showing cross-reactivity with other allergens (more than 50 allergy reports available in English, French and German) and illustrations.

About Abionic
Established in 2010, Abionic SA is ideally positioned at the boundaries of medical technology, biotechnology and nanotechnology. As a spin-off from EPFL (Swiss Federal Institute of Technology Lausanne, Switzerland), Abionic uses these highly advanced technologies to provide the medical profession with a novel diagnostic tool designed to give patients personal allergy profiles. Abionic aims to become an important international player in the field of personalized medicine, in particular in allergy detection.

Abionic is operating with a high level of vertical integration, handling most parts of the value chain. The abioSCOPE (reader), the abioKIT (capsule with biosensors) and the abioGUIDE (mobile application) have been engineered and are currently assembled in-house.

0Comments

More news about

Abionic SA

Company profiles on startup.ch

Abionic SA

rss